Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high risk for hepatocellular carcinoma
Authors:
Open Access
- 28 September 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 32 (1) , 63-68
Abstract
To investigate the roles of mutations in enhancer II (Enh II) and basal core promoter (BCP) of hepatitis B virus (HBV) in hepatocellular carcinoma (HCC), we determined the sequence of Enh II/BCP in 152 HCC and 136 non-HCC patients from a high-incidence area of East China. A longitudinal study was conducted on 21 cases in which serial plasma samples were available before HCC. In total, six point mutations, including T1653, V1753, T1762, A1764, T1766 and A1768, were found to occur more frequently in HCC patients. Multivariate analysis showed that the T1653 [odds ratio (OR), 2.07; 95% confidence interval (CI), 1.114–3.845] and V1753 (OR, 3.099; 95% CI, 1.520–6.317) were independent factors that were associated with HCC. Although a T1762/A1764 double mutation was found in 73.0% of the HCC patients and 66.9% of the non-HCC patients, if the combined pattern with other adjacent mutations was not taken into account, it alone showed a lower frequency in HCC patients compared with non-HCC patients (19.7 versus 34.6%, P = 0.005). Interestingly, while the OR of HCC patients with a double mutation was only 0.393 (95% CI, 0.234–0.660), it increased to 1.861 (95% CI, 1.161–2.984) with a triple mutation and to 4.434 (95% CI, 1.630–12.063) with a quadruple mutation. The longitudinal study demonstrated that the mutations in Enh II/BCP accumulated during the development of HCC. In conclusion, the T1653 and V1753 mutations were independent risk factors for HCC in East China. The T1762/A1764 double mutation was necessary but not sufficient to produce an association between Enh II/BCP mutations and HCC.Keywords
This publication has 39 references indexed in Scilit:
- Associations Between Hepatitis B Virus Mutations and the Risk of Hepatocellular Carcinoma: A Meta-AnalysisJNCI: Journal of the National Cancer Institute, 2009
- Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 2008
- Effect of basal core promoter and pre-core mutations on hepatitis B virus replicationJournal of General Virology, 2008
- Clinical and Virological Characteristics of Hepatitis B Virus Subgenotypes Ba, C1, and C2 in ChinaJournal of Clinical Microbiology, 2007
- Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinomaJournal of Hepatology, 2006
- Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinomaJournal of Hepatology, 2006
- T1653 Mutation in the Box a Increases the Riskof Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Genotype C InfectionClinical Infectious Diseases, 2006
- Differences of Hepatocellular Carcinoma Patients with Hepatitis B Virus Genotypes of Ba, Bj or C in JapanIntervirology, 2005
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- Hepatitis B e antigen-negative chronic hepatitis b in Hong KongHepatology, 2000